In 2 short‑term randomised controlled trials (RCTs: n=553) brimonidine tartrate gel was statistically significantly more effective than vehicle gel in reducing erythema in people with a clinical ...
- Galderma portfolio expands to offer a fast onset and long-acting alpha-2 adrenergic receptor agonist - Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today ...
For more information about this new treatment, visit www.mirvaso.com. Important Safety Information - Mirvaso® Gel Indication: Mirvaso ® (brimonidine) Topical Gel, 0.33%* is an alpha adrenergic agonist ...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing of brimonidine tartrate 3 mg/g topical gel (Mirvaso, Galderma) for the symptomatic ...
LAUSANNE, Switzerland, Sept. 11, 2017 /PRNewswire/ -- Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were ...
If you experience persistent facial redness, blushing, acne-like breakouts, visible blood vessels and or burning, itching or stinging on your face(1), it may be a chronic inflammatory skin condition ...
FORT WORTH, Texas--(BUSINESS WIRE)--Galderma Laboratories, L.P., a global leader focused on medical treatment options in dermatology and skin health and the maker of Cetaphil®, today announced the ...
Scientists aren’t entirely sure what causes rosacea, or why it intensifies as you get older, but they have some theories.
In 2 short‑term randomised controlled trials (RCTs: n=553) brimonidine tartrate gel was statistically significantly more effective than vehicle gel in reducing erythema in people with a clinical ...
Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. Rosacea is ...
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso(R) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results